Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.48 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.47 |
| ▸ | BCHE | P06276 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL184071 | 0.87 | MEN1 (0.56) | SIGMAR1BCHEACHE | |
| SCHEMBL13951338 | 0.87 | ACHE (0.47) | SIGMAR1MCHR1BCHEACHE | |
| SCHEMBL8126942 | 0.86 | CHRM2 (0.47) | SIGMAR1MCHR1FKBP1A | |
| Hydrochloric Acid SCHEMBL184070 | 0.86 | MEN1 (0.55) | SIGMAR1 | |
| SCHEMBL350213 | 0.86 | FKBP1A (0.47) | SIGMAR1BCHEACHEFKBP1A | |
| SCHEMBL3709844 | 0.85 | KMT2A (0.50) | SIGMAR1BCHEACHE | |
| Hydrochloric Acid SCHEMBL17611756 | 0.85 | FKBP1A (0.47) | SIGMAR1BCHEACHEFKBP1A | |
| SCHEMBL15836211 | 0.85 | CYP2D6 (0.47) | SIGMAR1MCHR1ACHE | |
| Hydrochloric Acid SCHEMBL5974110 | 0.83 | ACHE (0.49) | SIGMAR1BCHEACHE | |
| Hydrochloric Acid SCHEMBL5974104 | 0.83 | ACHE (0.49) | SIGMAR1BCHEACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11613532-B2 | Compounds active towards nuclear receptors | NUEVOLUTION A/S (DK) | 2023-03-28 | — | — | US | disclosed |
| EP-4126875-A1 | COMPOUNDS ACTIVE TOWARDS NUCLEAR RECEPTORS | Nuevolution A/S (DK) | 2023-02-08 | — | — | EP | disclosed |
| US-20220098182-A1 | COMPOUNDS ACTIVE TOWARDS NUCLEAR RECEPTORS | NUEVOLUTION A/S (DK) | 2022-03-31 | — | — | US | disclosed |
| US-20210355115-A1 | ISOXAZOLE CARBOXAMIDE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2021-11-18 | — | — | US | disclosed |
| US-20210355115-A1 | ISOXAZOLE CARBOXAMIDE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2021-11-18 | — | — | US | disclosed |
| WO-2021198956-A1 | COMPOUNDS ACTIVE TOWARDS NUCLEAR RECEPTORS | NUEVOLUTION A/S (DK) | 2021-10-07 | — | — | WO | disclosed |
| WO-2021198956-A1 | COMPOUNDS ACTIVE TOWARDS NUCLEAR RECEPTORS | NUEVOLUTION A/S (DK) | 2021-10-07 | — | — | WO | disclosed |
| CN-113056455-A | Isoxazole carboxamide compounds and uses thereof | 诺华股份有限公司 | 2021-06-29 | — | — | CN | disclosed |
| CN-103896826-B | The method of asymmetric synthesis of (3R, 4R)-3-methylamino-4-methyl piperidine of nitrogen protection, relevant intermediate and method for preparing raw material | 上海朴颐化学科技有限公司 | 2016-08-03 | — | — | CN | disclosed |
| CN-103896826-A | Asymmetric synthesis method of nitrogen protected (3R,4R)-3-methylamino-4-methylpiperidine, and relevant intermediate and raw material preparation method | SHANGHAI PUYI CHEMICAL CO LTD | 2014-07-02 | — | — | CN | disclosed |
| US-20090105124-A1 | HETEROCYCLIC MODULATORS OF TGR5 | KALYPSYS, INC. (US) | 2009-04-23 | — | — | US | disclosed |
| WO-2009026241-A1 | HETEROCYCLIC MODULATORS OF TGR5 | KALYPSYS, INC. (US) | 2009-02-26 | — | — | WO | disclosed |
| US-7414131-B2 | Bicycloheteroarylamine compounds as ion channel ligands and uses thereof | RENOVIS, INC. (US) | 2008-08-19 | — | — | US | disclosed |
| US-7414131-B2 | Bicycloheteroarylamine compounds as ion channel ligands and uses thereof | RENOVIS, INC. (US) | 2008-08-19 | — | — | US | disclosed |
| US-7312330-B2 | Bicycloheteroarylamine compounds as ion channel ligands and uses thereof | RENOVIS, INC. (US) | 2007-12-25 | — | — | US | disclosed |
| US-7312330-B2 | Bicycloheteroarylamine compounds as ion channel ligands and uses thereof | RENOVIS, INC. (US) | 2007-12-25 | — | — | US | disclosed |
| US-20070155716-A1 | HCV INHIBITING BI-CYCLIC PYRIMIDINES | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2007-07-05 | — | — | US | disclosed |
| US-20070155716-A1 | HCV INHIBITING BI-CYCLIC PYRIMIDINES | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2007-07-05 | — | — | US | disclosed |
| US-7223766-B2 | Bi-cyclic pyrimidine inhibitors of TGFβ | SCIOS, INC. (US) | 2007-05-29 | — | — | US | disclosed |
| US-7223766-B2 | Bi-cyclic pyrimidine inhibitors of TGFβ | SCIOS, INC. (US) | 2007-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210355115-A1 | ISOXAZOLE CARBOXAMIDE COMPOUNDS AND USES THEREOF | SLC26A4, ALDH5A1, SLC8B1 | SIGMAR1 2857/4885MCHR1 1817/4885BCHE 3178/4885 |
| US-20070155716-A1 | HCV INHIBITING BI-CYCLIC PYRIMIDINES | UMPS, NUDT1, PNP | SIGMAR1 3278/4885MCHR1 4743/4885BCHE 1598/4885 |
| US-20220098182-A1 | COMPOUNDS ACTIVE TOWARDS NUCLEAR RECEPTORS | NCOA1, NR1H2, NCOA3 | SIGMAR1 200/4885MCHR1 2198/4885BCHE 3363/4885 |
| US-11613532-B2 | Compounds active towards nuclear receptors | NCOA1, NR1H2, NCOA3 | SIGMAR1 200/4885MCHR1 2198/4885BCHE 3363/4885 |
| US-20090105124-A1 | HETEROCYCLIC MODULATORS OF TGR5 | GPBAR1, GPR119, GRK5 | SIGMAR1 669/4885MCHR1 1129/4885BCHE 1055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.